focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

8 Apr 2024 16:03

RNS Number : 7346J
Evgen Pharma PLC
08 April 2024
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BSVYN304

Issuer Name

EVGEN PHARMA PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Rathbones Investment Management Ltd

City of registered office (if applicable)

London

Country of registered office (if applicable)

United Kingdom

Name

City of registered office

Country of registered office

Investec Wealth & Investment Limited

London

United Kingdom

4. Details of the shareholder

Name

City of registered office

Country of registered office

Hero Nominees Limited

St Peter Port

Guernsey

Ferlim Nominees Limited

London

United Kingdom

Rathbone Nominees Limited

London

United Kingdom

5. Date on which the threshold was crossed or reached

05-Apr-2024

6. Date on which Issuer notified

08-Apr-2024

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

6.034700

0.000000

6.034700

25789246

Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BSVYN304

25789246

6.034700

Sub Total 8.A

25789246

6.034700%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Rathbones Group PLC

Rathbones Investment Management Limited

6.033600

6.033600%

Rathbones Group PLC

Investec Wealth & Investment Limited

0.001100

0.001100%

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

None

12. Date of Completion

08-Apr-2024

13. Place Of Completion

Port of Liverpool Building, Liverpool L3 1NW

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLGZGGDKRZGDZM
Date   Source Headline
13th Dec 20177:00 amRNSCollaboration with King's College London
11th Dec 20177:15 amRNSHardman Res.: Funded to the end of Phase II trials
8th Dec 20177:15 amRNSPlacing and Notice of General Meeting
8th Dec 20177:00 amRNSInterim Results
23rd Nov 201711:05 amRNSSecond Price Monitoring Extn
23rd Nov 201711:00 amRNSPrice Monitoring Extension
4th Oct 20177:00 amRNSFirst European Patent Grant
31st Aug 20177:00 amRNSIssue of Equity and Total Voting Rights
2nd Aug 20171:00 pmRNSSFX-01 data published in Peer Reviewed Journal
27th Jul 20177:00 amRNSResult of AGM
26th Jul 20177:00 amRNSAGM Statement
11th Jul 201712:30 pmRNSCharity-funded Study of SFX-01 in TNBC
21st Jun 201710:00 amRNSPosting of Annual Report and AGM Notice
21st Jun 20177:15 amRNSHardman Research: Making clinical progress
13th Jun 20177:00 amRNSFull Year Results
1st Jun 20177:00 amRNSCompassionate Use Programme and Trials Update
25th May 20177:00 amRNSNotice of Preliminary Results
3rd Apr 20172:15 pmRNSDirectorate Change
28th Mar 20172:45 pmRNSFurther US Patent Grant
6th Mar 20177:00 amRNSIssue of Equity, PDMR Shareholding and TVR
14th Feb 20171:30 pmRNSPatent Grant in the United States
13th Feb 20177:00 amRNSServices Agreement with APTrans
17th Jan 20177:00 amRNSFirst Patient Dosed in Breast Cancer Trial
17th Jan 20177:00 amRNSAppointment of CFO and Head of Clinical Operations
11th Jan 20177:00 amRNSPositive DSMB Review of SAS Trial
5th Dec 20167:00 amRNSHalf Yearly Report
29th Nov 201611:53 amRNSHardman Research: Clinical sulforaphane potential
17th Nov 20167:00 amRNSNotice of Interim Results
1st Nov 201612:30 pmRNSGrant of Options
15th Sep 20167:00 amRNSUpdate re SFX-01 Data at ECTRIMS 2016
8th Sep 20163:30 pmRNSPresentation of SFX-01 Data at ECTRIMS 2016
24th Aug 20163:15 pmRNSOrphan Designation in the USA in SAH
17th Aug 20167:00 amRNSApproval for Phase II Study in Breast Cancer
24th Jun 20163:36 pmRNSResult of AGM
9th Jun 20167:00 amRNSGrant of Options
2nd Jun 20167:00 amRNSPosting of Annual Report and AGM Notice
31st May 20167:00 amRNSFinal Results
9th May 20167:00 amRNSNotification of Preliminary Results
3rd May 20167:00 amRNSFirst Patient Dosed in Phase II Trial
2nd Mar 20167:00 amRNSApproval of Phase II Clinical Trial in SAH
19th Jan 20163:23 pmRNSCorrection: Director Share Purchases
19th Jan 20167:00 amRNSDirector Share Purchases
11th Jan 20167:00 amRNSExercise of Options
4th Jan 20167:00 amRNSAppoints Chief Medical Officer
7th Dec 20157:00 amRNSHalf Yearly Report
23rd Nov 20157:00 amRNSExpands Pipeline with Novel Compounds
16th Nov 20157:00 amRNSNotification of Half Year Results
23rd Oct 201511:45 amRNSNotification of Major Interest in Shares
21st Oct 20157:00 amRNSFirst Day of Dealings
21st Dec 20114:30 pmRNSTemporary Suspension Evolution Group PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.